Lipocine Inc - ESG Rating & Company Profile powered by AI
Alternative corporations in the rating industry group for Lipocine Inc are displayed below. This ESG score covers seventeen United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Peace, Justice & Strong Institutions'. This ESG assessment for Lipocine Inc indicates the company's reporting of the UN SDGs.
Lipocine Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.3; made up of an environmental score of 1.6, social score of 6.4 and governance score of 8.0.
5.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 645 | Biomm SA | 5.4 | High |
| 645 | Tiziana Life Sciences PLC | 5.4 | High |
| 658 | Lipocine Inc | 5.3 | High |
| 658 | Cellmid Ltd | 5.3 | High |
| 658 | Bio-Techne Corp | 5.3 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Lipocine Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Lipocine Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Lipocine Inc report the average age of the workforce?
Sign up for free to unlockDoes Lipocine Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Lipocine Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Lipocine Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Lipocine Inc offer flexible work?
Sign up for free to unlockDoes Lipocine Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Lipocine Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Lipocine Inc conduct supply chain audits?
Sign up for free to unlockDoes Lipocine Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Lipocine Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Lipocine Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Lipocine Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Lipocine Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Lipocine Inc disclose water use targets?
Sign up for free to unlockDoes Lipocine Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Lipocine Inc have a product recall in the last two years?
Sign up for free to unlockDoes Lipocine Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Lipocine Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Lipocine Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Lipocine Inc disclose parental leave metrics?
Sign up for free to unlockDoes Lipocine Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Lipocine Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Lipocine Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Lipocine Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Lipocine Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Lipocine Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Lipocine Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Lipocine Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Lipocine Inc disclose its waste policy?
Sign up for free to unlockDoes Lipocine Inc report according to TCFD requirements?
Sign up for free to unlockDoes Lipocine Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Lipocine Inc disclose energy use targets?
Sign up for free to unlockDoes Lipocine Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Lipocine Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Lipocine Inc
These potential risks are based on the size, segment and geographies of the company.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.